Vaxxinity’s Parkinson’s candidate UB-312 demonstrates efficacy in publication

Vaxxinity announced that Nature Medicine has published exploratory data from the company’s Phase 1 clinical trial of UB-312 in patients with Parkinson’s disease. The trial included measures of clinical efficacy, as well as exploratory research funded by The Michael J. Fox Foundation assessing target engagement in collaboration with the Mayo Clinic and UTHealth Houston. UB-312-induced antibodies significantly decreased levels of aggregated alpha-synuclein, a key pathology in PD and other synucleinopathies. This suggests that UB-312 can help to eliminate the buildup of harmful, toxic forms of the protein alphaSyn in the brain. Patients with detectable UB-312-induced antibodies in cerebrospinal fluid exhibited significant improvement in motor experiences of daily living. The Phase 1 successfully met its primary outcome measures, demonstrating UB-312 was generally well-tolerated and induced anti-alphaSyn antibody responses in healthy volunteers and PD patients. 12 out of 13 PD patients who completed dosing developed anti-alphaSyn antibodies. PD patients with UB-312-induced antibodies in CSF had significantly less alphaSyn aggregation and pS129-alphaSyn vs. patients without detectable CSF antibody titers.